We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals

204 hedge funds and large institutions have $3.91B invested in Ionis Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 61 increasing their positions, 75 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

254% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 13

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

38% more capital invested

Capital invested by funds: $2.84B → $3.91B (+$1.07B)

18% more funds holding

Funds holding: 173204 (+31)

19% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 75

31% less call options, than puts

Call options by funds: $40.4M | Put options by funds: $58.5M

Holders
204
Holders Change
+31
Holders Change %
+17.92%
% of All Funds
6.61%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.16%
New
46
Increased
61
Reduced
75
Closed
13
Calls
$40.4M
Puts
$58.5M
Net Calls
-$18M
Net Calls Change
-$24.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$638M +$22.9M +765,455 +5%
Artisan Partners
2
Artisan Partners
Wisconsin
$399M +$43.9M +1,468,994 +16%
Vanguard Group
3
Vanguard Group
Pennsylvania
$275M +$19M +634,403 +9%
ClearBridge Investments
4
ClearBridge Investments
New York
$271M +$11.7M +393,043 +6%
BB
5
BB Biotech
Switzerland
$270M -$16.9M -566,587 -7%
BFA
6
BlackRock Fund Advisors
California
$160M +$17.9M +598,421 +16%
WRF
7
Waddell & Reed Financial
Kansas
$159M +$10.7M +357,100 +9%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$128M -$12.6M -422,710 -11%
BIT
9
BlackRock Institutional Trust
California
$115M -$5.68M -190,241 -6%
State Street
10
State Street
Massachusetts
$99.3M -$1.92M -64,158 -2%
PA
11
Pinnacle Associates
New York
$77.5M -$1.63M -54,603 -3%
Franklin Resources
12
Franklin Resources
California
$73.4M +$3.71M +124,240 +7%
Jennison Associates
13
Jennison Associates
New York
$71.8M -$9.93M -332,408 -15%
Lord, Abbett & Co
14
Lord, Abbett & Co
New Jersey
$66.8M -$9.82M -328,657 -16%
TAM
15
Tocqueville Asset Management
New York
$62.3M -$8.43M -282,194 -15%
Northern Trust
16
Northern Trust
Illinois
$60.9M -$508K -17,003 -1%
AllianceBernstein
17
AllianceBernstein
Tennessee
$55.3M +$782K +26,191 +2%
BA
18
BlackRock Advisors
Delaware
$49.9M -$6.15M -205,926 -13%
EAM
19
Eagle Asset Management
Florida
$35.2M +$27.4M +917,068 New
GIM
20
Granahan Investment Management
Massachusetts
$31.6M -$2.05M -68,500 -8%
VAM
21
Visium Asset Management
New York
$29.7M +$2.54M +85,021 +12%
Wells Fargo
22
Wells Fargo
California
$29.4M -$13M -434,905 -36%
Deutsche Bank
23
Deutsche Bank
Germany
$27.5M +$16M +534,281 +271%
Norges Bank
24
Norges Bank
Norway
$27.3M +$7.26M +243,186 +50%
PC
25
PointState Capital
New York
$27.2M +$21.7M +725,000 New

IONS Hedge Fund Activity: Q3 2013 in Review

204 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2013, worth a combined $3.91B — up 38% from $2.84B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new IONS positions and 13 closed out — a net gain of 33 holders — while 61 added to existing stakes and 75 trimmed.

The largest buyer was Artisan Partners, adding an estimated $43.9M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $29.9M.

  • 204 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2013, up from 173 in Q2 2013.
  • Funds reported $3.91B of Ionis Pharmaceuticals stock for Q3 2013, up 38% quarter-over-quarter.
  • 46 funds opened new Ionis Pharmaceuticals positions in Q3 2013 and 13 closed out, a net change of +33 holders.
  • The largest Ionis Pharmaceuticals buyer in Q3 2013 was Artisan Partners, an estimated $43.9M added.
  • The largest Ionis Pharmaceuticals seller in Q3 2013 was BNP Paribas Financial Markets, an estimated $29.9M sold.

Based on aggregated 13F filings for Q3 2013.